KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Moderna (MRNA) Return on Sales (2017 - 2026)

Moderna (MRNA) has disclosed Return on Sales for 10 consecutive years, with 3.45% as the latest value for Q1 2026.

  • For Q1 2026, Return on Sales rose 554.0% year-over-year to 3.45%; the TTM value through Mar 2026 reached 1.44%, down 36.0%, while the annual FY2025 figure was 1.45%, 35.0% down from the prior year.
  • Return on Sales hit 3.45% in Q1 2026 for Moderna, down from 1.22% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.6% in Q1 2022 and bottomed at 8.99% in Q1 2025.
  • Average Return on Sales over 5 years is 2.31%, with a median of 1.16% recorded in 2024.
  • Year-over-year, Return on Sales crashed -708bps in 2024 and then skyrocketed 554bps in 2026.
  • Moderna's Return on Sales stood at 0.29% in 2022, then plummeted by -73bps to 0.08% in 2023, then plummeted by -1602bps to 1.16% in 2024, then dropped by -5bps to 1.22% in 2025, then crashed by -183bps to 3.45% in 2026.
  • According to Business Quant data, Return on Sales over the past three periods came in at 3.45%, 1.22%, and 0.2% for Q1 2026, Q4 2025, and Q3 2025 respectively.